Utrecht University and Bruker Corporation Announce Collaboration

To Develop Methods for Studying Protein Structures and Interactions by Mass Spectrometry Crosslinking Mass Spectrometry (XL-MS) Now Can Leverage the PhoX Crosslinker and TIMS/PASEF Methods with the Large-Scale Use of Accurate Collision Cross Sections

Bruker Corporation today announced a collaboration with Utrecht University to advance the study of the 3-D structures and interactions of proteins by mass spectrometry. The laboratory of Albert Heck at Utrecht University has been a leader in proteomics and the study of protein structure and interactions by mass spectrometry for over two decades. Richard Scheltema recently joined Utrecht University as group leader to focus on crosslinking mass spectrometry (XL-MS) for structural and interaction proteomics.

The collaborative work will focus on the development of TIMS (Trapped Ion Mobility Spectrometry) and PASEF (Parallel Accumulation Serial Fragmentation) methods, along with crosslinkers and XL-MS software for the timsTOF Pro 4D-Proteomics mass spectrometer, in order to take advantage of its unique large-scale, accurate CCS workflows. These have been described in the foundational paper “Benefits of Collisional Cross Section Assisted Precursor Selection (caps-PASEF) for Cross-linking Mass Spectrometry “, just published in a breakthrough paper in Molecular and Cellular Proteomics.1

Bruker Corporation plans to commercialize the results of the collaboration as integrated solutions for the study of protein structures and interactions using XL-MS. Combining the novel, enrichable PhoX crosslinker2, developed by Heck and Scheltema, with the extreme speed and sensitivity of PASEF methods on the timsTOF Pro platform, enables the discovery of more crosslinked products which yield more information about protein structures and interactions. Advanced analysis software is key, as XL-MS data is more complex and even more information-rich than typical shot-gun proteomics experiments. Scheltema is working on enabling the innovative XlinkX software to process TIMS/PASEF data and making it available to the community of timsTOF Pro users.

Albert Heck of Utrecht University commented: “We are delighted to work with Bruker Corporation on the further development of workflows for XL-MS that take advantage of the speed of PASEF and the unique large-scale, accurate CCS data to enhance the detection of crosslinks in XL-MS. We are excited by the initial results published in Molecular and Cellular Proteomics and look forward to advancing XL-MS even further. We are also interested in other applications of ion mobility separation and CCS on the timsTOF Pro to glycoproteomics and top-down proteomics.”

Dr. Gary Kruppa, the Vice President of Proteomics at Bruker, said: “Having personally been involved in some of the conceptual work in XL-MS in 2001 at Sandia National Laboratory, I believe the advances made by Heck’s group will make this technique more routinely available for structural biology studies using the timsTOF Pro. Our collaboration with Utrecht University will accelerate adoption of XL-MS within the broader structural and interaction proteomics community.”

Richard Scheltema of Utrecht University stated: “My group intends to push the boundaries of PASEF to enhance XL-MS workflows by making them CCS-aware. We have a significant ongoing effort in bioinformatics applied to analyzing XL-MS data using our XlinkX software.3,4 We are excited to work with the open data-format architecture of the timsTOF Pro in XlinkX to develop code that can use large-scale, accurate CCS values for the identification of crosslinks and to further improve false discovery rate (FDR) calculations.”

  1. Benefits of Collisional Cross Section Assisted Precursor Selection (caps-PASEF) for Cross-linking Mass Spectrometry. Steigenberger B, van den Toorn H, Bijl E, Greisch JF, Räther O, Lubeck M, Pieters RJ, Heck AJR, Scheltema RA., Mol Cell Proteomics, 2020 Jul 21:mcp.RA120.002094. doi: 10.1074/mcp.RA120.002094. Online ahead of print.
  2. PhoX: An IMAC-Enrichable Cross-Linking Reagent. Steigenberger B, Pieters RJ, Heck AJR, Scheltema RA. ACS Cent Sci. 2019 Sep 25;5(9):1514-1522.
  3. Proteome-wide profiling of protein assemblies by cross-linking mass spectrometry. Liu F, Rijkers DT, Post H, Heck AJ. Nat Methods. 2015 Dec 12(12):1179-84. doi: 10.1038/nmeth.3603
  4. Klykov, O., Steigenberger, B., Pektaş, S. et al. Efficient and robust proteome-wide approaches for cross-linking mass spectrometry. Nat Protoc 2018 Dec 13, 2964–2990. https://doi.org/10.1038/s41596-018-0074-x

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version